European Commission responds to "easy market access" claims
This article was originally published in RAJ Devices
Executive Summary
The European Commission is unable to say whether market access for medical devices is easier in the European Union than it is in the US, as has been suggested1,2. Any comparative advantage of the EU with regard to easy market access that does exist, however, will “slightly shrink” when new requirements for clinical investigation become effective, the commission says, adding that there is nothing wrong with easy access as long as it is not linked to a low safety standard.
You may also be interested in...
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
EU Accelerated Assessment Tracker
The EU filing for AstraZeneca’s nirsevimab is being reviewed under the accelerated pathway at the European Medicines Agency. Also, Janssen should know by now whether its planned filing for Zejula plus Zytiga will get the same treatment – as should SIFI for its planned Akantior filing.
AZ Secures EU Fast-Tack Review For Nirsevimab
There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.